Chlorpropamide-induced changes in patients with hyperparathyroidism.
Ten patients with primary hyperparathyroidism were placed on a constant 30 mEq of calcium and 120 meq of sodium diet, and alterations in their calcium balance in response to standard oral doses of chlorpropamide were studied over a 4 day control period and a 4 day treatment period. The 10 patients treated with chlorpropamide significantly increased the urinary excretion of calcium and sodium and decreased the excretion of cyclic adenosine monophosphate (AMP). The serum calcium was lowered in six of the patients treated with chlorpropamide, and three of these patients, who had diabetes mellitus and either refused or were too ill for parathyroidectomy, continued to receive chlorpropamide for periods of 9 to 36 months. These three patients experienced prolonged lowering of the serum calcium level and became less confused, lethargic, and fatigued. The interrelationships between the chlorpropamide-induced changes in excretion of calcium, sodium, and cyclic AMP still must be clarified.
D000249:Adenosine Monophosphate / Q000652:urine; D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood / Q000652:urine; D002747:Chlorpropamide / Q000008:administration & dosage / Q000627:therapeutic use*; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000652:urine
D000249:Adenosine Monophosphate; D012964:Sodium; D002118:Calcium; D002747:Chlorpropamide